2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Melanoma
7
Ovarian Neoplasms
6
Lung Neoplasms
5
Carcinoma, Non-Small-Cell Lung
5
Sarcoma, Ewing
4
Leukemia
4
Uterine Neoplasms
3
Uterine Cervical Neoplasms
3
Neoplasms
3
Multiple Myeloma
3
Kidney Neoplasms
3
Gliosarcoma
3
Glioblastoma
3
Central Nervous System Neoplasms
3
Carcinoma, Renal Cell
3
Astrocytoma
3
Sarcoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms, Plasma Cell
2
Lymphoma, Follicular
2
Lymphoma
2
Fallopian Tube Neoplasms
2
Congenital Abnormalities
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Breast Neoplasms
2
Brain Neoplasms
2
Thymoma
1
Small Cell Lung Carcinoma
1
Interventions
Temozolomide
1
Sodium Chloride
1
Methotrexate
1
Irinotecan
1
FANG vaccine
1
Doxorubicin
1
Cisplatin
1
Adrenal Cortex Hormones
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Connective Tissue
×
FANG vaccine
×
Clear all
NCT03495921
2023-04-26
VITA
Gradalis, Inc.
Phase 3
Terminated
32 enrolled
13 charts